Interaction of Approved Drugs with Synaptic Vesicle Protein 2A
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Levetiracetam (LEV) and its recently approved derivative brivaracetam are anti‐epileptic drugs with a unique mechanism of action. The synaptic vesicle protein 2A (SV2A) was previously identified as their main target. In the current study, we tested a collection of 500 approved drugs for interaction with the human SV2A protein expressed in Chinese hamster ovary cells. Competition binding studies were performed using cell lysates with high SV2A expression and [3 H]brivaracetam as a radioligand. A hit rate of 3% was obtained, defined as compounds that inhibited radioligand binding by more than 90% at a screening concentration of 20 μM. Subsequent concentration–inhibition curves revealed the antihistaminic prodrug loratadine (Ki = 1.16 μM) and the antimalarial drug quinine (Ki = 2.03 μM) to be the most potent SV2A protein ligands of the investigated drug library. Both compounds were similarly potent as LEV (Ki = 1.74 μM), providing structurally novel scaffolds for SV2A ligands. A pharmacophore model was established, which indicated steric and electronic conformities of brivaracetam with the new SV2A ligands, and preliminary structure–activity relationships were determined. The anti‐convulsive effects of the natural product quinine may – at least in part – be explained by interaction with SV2A. Loratadine and quinine represent new lead structures for anti‐epileptic drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ultimately, this tracer did not progress, probably due to its low binding affinity to SV2A (K i = 1.74 µM)”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [109]
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Jasper's Basic Mechanisms of the Epilepsies
(2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.001.0001 · Cited by 1,143
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria
Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J., & D'Alessandro, U. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-144 · Cited by 1,007
Epilepsy across the spectrum: Promoting health and understanding.
England, M. J., Liverman, C. T., Schultz, A. M., & Strawbridge, L. M. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.06.016 · Cited by 732
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction
Goldberg, E. M., & Coulter, D. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3482 · Cited by 542
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
An improved force field (MM4) for saturated hydrocarbons
Allinger, N. L., Chen, K., & Lii, J.-H. (1996) · Journal of Computational Chemistry · doi:10.1002/(sici)1096-987x(199604)17:5/6<642::aid-jcc6>3.0.co;2-u · Cited by 366
Drug repurposing: far beyond new targets for old drugs
Oprea, T. I., & Mestres, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9390-1 · Cited by 285
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P., & Wülfert, E. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00436-o · Cited by 255
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253
Quinoline antimalarials: Mechanisms of action and resistance
Foley, M., & Tilley, L. (1997) · International Journal for Parasitology · doi:10.1016/s0020-7519(96)00152-x · Cited by 229
Quinine blocks specific gap junction channel subtypes
Srinivas, M., Hopperstad, M. G., & Spray, D. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191206198 · Cited by 211
Flexible Alignment of Small Molecules
Labute, P., Williams, C., Feher, M., Sourial, E., & Schmidt, J. M. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002634 · Cited by 192
An Introduction to Antiepileptic Drugs
Perucca, E. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.463007.x · Cited by 184
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Kaminski, R. M., Matagne, A., Leclercq, K., Gillard, M., Michel, P., Kenda, B., Talaga, P., & Klitgaard, H. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.021 · Cited by 169
Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy
Obach, R. S. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005439 · Cited by 159
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Quinine, a Blocker of Neuronal Cx36 Channels, Suppresses Seizure Activity in Rat Neocortex In Vivo
Gajda, Z., Szupera, Z., Blazsó, G., & Szente, M. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00254.x · Cited by 128
Synaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
Kaminski, R. M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 116
Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission
Yang, X., Weisenfeld, A., & Rothman, S. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.01132.x · Cited by 111
Binding of Quinine to Plasma Proteins in Falciparum Malaria
Silamut, K., Warrell, D. A., Looareesuwan, S., & White, N. J. (1985) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1985.34.681 · Cited by 104
Kay, G. G., & Harris, A. G. (1999) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1999.0290s3147.x · Cited by 93
High Throughput Screening: Methods and Protocols
Janzen, W. P. (2002) · Cited by 77
Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats
Löscher, W., Reißmüller, E., & Ebert, U. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(00)00108-x · Cited by 76
Mercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., Kenda, B., Lallemand, B., Michel, P., Montel, F., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300482 · Cited by 68
Quinine Pharmacokinetic-Pharmacodynamic Relationships in Uncomplicated Falciparum Malaria
Pukrittayakamee, S., Wanwimolruk, S., Stepniewska, K., Jantra, A., Huyakorn, S., Looareesuwan, S., & White, N. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3458-3463.2003 · Cited by 63
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Gillard, M. R., Fuks, B., Michel, P., Vertongen, P., Massingham, R., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.032 · Cited by 61
Anticonvulsive effects of quinine on penicillin-induced epileptiform activity: An in vivo study
Bostanci, M. Ö., & Bağırıcı, F. (2007) · Seizure · doi:10.1016/j.seizure.2006.11.007 · Cited by 55
Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission
Yang, X., & Rothman, S. M. (2009) · Seizure · doi:10.1016/j.seizure.2009.07.004 · Cited by 51
Antiepileptic effects of quinine in the pentylenetetrazole model of seizure
Nassiri‐Asl, M., Zamansoltani, F., & Torabinejad, B. (2008) · Seizure · doi:10.1016/j.seizure.2008.08.002 · Cited by 44
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy
Matagne, A., Mǎrgineanu, D.-G., Potschka, H., Löscher, W., Michel, P., Kenda, B., & Klitgaard, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.04.024 · Cited by 39
Inhibitory Effect of the H 1 Antagonist Loratadine on Histamine Release from Human Basophils
Miadonna, A., Milazzo, N., Lorini, M., Marchesi, E., & Tedeschi, A. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000236797 · Cited by 34
Daniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12192 · Cited by 28
Loratadine: A Nonsedating Antihistamine with Once-Daily Dosing
Barenholtz, H. A., & McLeod, D. C. (1989) · DICP · doi:10.1177/106002808902300601 · Cited by 22
Leclercq, K., & Kaminski, R. M. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.06.011 · Cited by 15
Antiepileptic properties of Quinine: A systematic review
Mwita, C. C., Mwai, L., & Newton, C. R. J. C. (2012) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.180404 · Cited by 14
PHARMACOKINETICS OF LORATADINE IN PEDIATRIC SUBJECTS
Lin, C., Radwanski, E., Affrime, M. B., & Cayen, M. N. (1995) · American Journal of Therapeutics · doi:10.1097/00045391-199506000-00011 · Cited by 9
Hildenbrand, S., Schoch, S., von Lehe, M., Surges, R., & Müller, C. E. (2012) · ChemMedChem · doi:10.1002/cmdc.201200183 · Cited by 9
Self-citationHildenbrand, S., Baqi, Y., & Müller, C. E. (2011) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1942 · Cited by 5
Self-citation
Research works printed but not linked: 5
- Kaminski R. M., 2012, Jaspers Basic Mechanisms of the Epilepsies
- S.Hildenbrand Ph.D. Thesis University of Bonn 2012.
- Clifford M., 2012, Ann. Neurosci, 19, 14
- Etemadi F., 2016, Iran. Biomed. J, 20, 266
- 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P · DOI · Paper page
Cited by
Onwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
“74 μM) [20], and thus the use of [(11)C]levetiracetam is unlikely to provide meaningful PET signals.”
BackgroundImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Onwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55
SV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
“However, the initial radioligand, 11C-levetiracetam (Cai et al., 2014), was abandoned due to its low binding affinity (Danish et al., 2017).”
Background
Metadata
- Authors
- Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Müller, Christa E.
- Venue
- Archiv der Pharmazie
- Publisher
- Wiley
- Published
- 2017-02-21
- Volume
- 350
- Issue
- 3-4
- ISSN
- 0365-6233 (ISSN-L)
- 1521-4184
- OpenAlex
- W2589165737
- Cited by
- 19
- References
- 45
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archiv der Pharmazie (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- SV2A, levetiracetam, brivaracetam, drug repurposing, approved drugs, loratadine, quinine, anticonvulsant mechanism, pharmacophore model, structure-activity relationship, radioligand binding
- MeSH terms
- Levetiracetam, Animals, Anticonvulsants, Cricetulus, Dose-Response Relationship, Drug, Humans, Ligands, Membrane Glycoproteins, Nerve Tissue Proteins, Piracetam, Pyrrolidinones, Quinine, Structure-Activity Relationship, Molecular Structure, CHO Cells, Loratadine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.